The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 48 | — | 20.1x | Near average | |
Growth | 67 | — | 5.6% | Above average | |
Quality | 13 | -64.7% | 7.6% | Below average | |
Safety | 25 | 0.3x | 0.4x | Below average | |
Capital Return | 20 | 0.00% | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Allogene Therapeutics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Allogene Therapeutics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Allogene stock shows a state of complete stability in the average price targets at 6.43 dollars over the past 30 days, with no revisions recorded by the four analysts covering the stock recently. Despite the large gap between the low (3.85 dollars) and the high (9 dollars), the current price of 2 dollars reflects a sharp discount from analyst estimates, indicating theoretical optimism that has not yet translated into price momentum in the market.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.